ATE477273T1 - Humanisierte antikoerper gegen gamma-interferon - Google Patents

Humanisierte antikoerper gegen gamma-interferon

Info

Publication number
ATE477273T1
ATE477273T1 AT99964004T AT99964004T ATE477273T1 AT E477273 T1 ATE477273 T1 AT E477273T1 AT 99964004 T AT99964004 T AT 99964004T AT 99964004 T AT99964004 T AT 99964004T AT E477273 T1 ATE477273 T1 AT E477273T1
Authority
AT
Austria
Prior art keywords
antibodies against
humanized antibodies
gamma interferon
against gamma
interferon
Prior art date
Application number
AT99964004T
Other languages
English (en)
Inventor
Maximiliano Vasquez
Nicholas Landolfi
Naoya Tsurushita
Cary Queen
Original Assignee
Facet Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facet Biotech Corp filed Critical Facet Biotech Corp
Application granted granted Critical
Publication of ATE477273T1 publication Critical patent/ATE477273T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99964004T 1998-12-01 1999-11-29 Humanisierte antikoerper gegen gamma-interferon ATE477273T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11052398P 1998-12-01 1998-12-01
PCT/US1999/028195 WO2000032634A1 (en) 1998-12-01 1999-11-29 Humanized antibodies to gamma-interferon

Publications (1)

Publication Number Publication Date
ATE477273T1 true ATE477273T1 (de) 2010-08-15

Family

ID=22333495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99964004T ATE477273T1 (de) 1998-12-01 1999-11-29 Humanisierte antikoerper gegen gamma-interferon

Country Status (12)

Country Link
US (2) US6329511B1 (de)
EP (1) EP1135415B1 (de)
JP (1) JP2002531466A (de)
KR (1) KR100483494B1 (de)
CN (1) CN1214043C (de)
AT (1) ATE477273T1 (de)
AU (1) AU764211C (de)
CA (1) CA2352572C (de)
DE (1) DE69942671D1 (de)
HK (1) HK1044159A1 (de)
MX (1) MXPA01005515A (de)
WO (1) WO2000032634A1 (de)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030229208A1 (en) * 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
DE69322289T2 (de) * 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
US20030059428A1 (en) * 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
US20030223995A1 (en) * 1996-12-23 2003-12-04 Advanced Biotherapy, Inc. Treatment of pemphigus vulgaris
US20030086925A1 (en) * 1996-12-23 2003-05-08 Advanced Biotherapy, Inc. Treatment of autoimmune diseases
EP1039931B1 (de) * 1997-12-01 2005-04-27 Fang Fang Multivalente rekombinante antikörper zur behandlung von hrv infektionen
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
ATE477273T1 (de) * 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
EP1336654A1 (de) * 1998-12-09 2003-08-20 Protein Design Labs, Inc. Verfahren zur Behandlung von Psoriasis mittels anti-gamma Interferon Antikörpers
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CA2454358A1 (en) * 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
ES2556338T3 (es) 2001-10-10 2016-01-15 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7244592B2 (en) * 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
WO2003077947A1 (en) 2002-03-15 2003-09-25 Schering Corporation Methods of modulating cd200 receptors
JP2005529152A (ja) 2002-05-17 2005-09-29 プロテイン デザイン ラブス インコーポレイティド 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
US20050019323A1 (en) * 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
US20040052791A1 (en) * 2002-05-22 2004-03-18 Rolf Ehrhardt Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
US20040052790A1 (en) * 2002-09-18 2004-03-18 Advanced Biotherapy, Inc. Treatment of schizophrenia
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003285874A1 (en) * 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
CA2502668C (en) * 2002-10-17 2013-07-30 Amgen Inc. Fully human antibody fab fragments with human interferon-gamma neutralizing activity
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
EP2246363A1 (de) 2002-11-15 2010-11-03 Novartis Vaccines and Diagnostics, Inc. Verfahren zur Prävention und Behandlung von Krebsmetastasen und Knochenschwund, der mit Krebsmetastasen assoziiert ist
EP1587834B1 (de) 2002-12-23 2011-07-06 Schering Corporation Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
TWI357336B (en) 2003-03-10 2012-02-01 Schering Corp Uses of il-23 agonists and antagonists; related re
JP4685764B2 (ja) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
DK1734996T3 (da) 2004-04-02 2013-06-10 Univ California Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20050276806A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
TWI363091B (en) 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
CN101151277B (zh) 2005-01-27 2013-11-13 诺维莫尼公司 抗干扰素γ抗体及其使用方法
EP3050963B1 (de) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
EP2277916A3 (de) * 2005-07-28 2011-04-27 Novartis AG Verwendung von Antikörper zu M-CSF
EP1913027B1 (de) * 2005-07-28 2015-03-04 Novartis AG M-csf-spezifische monoklonale antikörper und anwendungen davon
EP1933869B1 (de) 2005-09-01 2009-10-14 Schering Corporation Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
WO2007053524A2 (en) * 2005-10-28 2007-05-10 The Florida International University Board Of Trustees Horse: human chimeric antibodies
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
IN2014DN10515A (de) * 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
BRPI0715332A2 (pt) 2006-08-04 2013-10-08 Novartis Ag Anticorpo, métodos de triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 útil para o tratamento de câncer, de alterar sistemicamente os anticorpos e triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 para o tratamento de câncer, de tratar um paciente que sofre de câncer, de alvejar uma célula tumoral que expressa epbh3, e de usar a célula hospedeira, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e kit.
NZ596834A (en) 2006-08-18 2013-06-28 Novartis Ag Prlr-specific antibody and uses thereof
EP2087002B1 (de) 2006-10-27 2014-09-24 Lpath, Inc. Zusammensetzungen und verfahren zur bindung von sphingosin-1-phosphat
JP5732182B2 (ja) * 2006-10-27 2015-06-10 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． 眼疾患と症状を処置するための組成物および方法
EP2101816B1 (de) 2006-12-07 2013-08-14 Novartis AG Antagonistische antikörper gegen ephb3
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
EP2056838B1 (de) 2007-02-28 2013-09-25 Merck Sharp & Dohme Corp. Kombinationstherapie zur behandlung von immunerkrankungen
LT2164992T (lt) 2007-05-30 2016-09-12 Lpath, Inc. Lizofosfatido rūgšties kompozicijos ir prisirišimo būdai
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US8604172B2 (en) * 2009-04-17 2013-12-10 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
JP5611820B2 (ja) 2007-06-25 2014-10-22 エスバテック − ア ノバルティスカンパニー エルエルシー 抗体の修飾方法並びに改善された機能特性を有する修飾された抗体
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
ES2687808T3 (es) * 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
KR20160074019A (ko) * 2007-12-05 2016-06-27 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
EP2261254A3 (de) 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
EP2620448A1 (de) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin-antikörper und Verfahren zu ihrer Verwendung
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA2740871A1 (en) 2008-10-16 2010-04-22 Cytonics Corporation Biomarkers and methods for detecting and treating spinal and joint pain
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
CN102573905A (zh) * 2008-12-05 2012-07-11 勒帕斯公司 利用抗脂类抗体晶体结构的抗体设计
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
WO2010098863A1 (en) * 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
PE20120562A1 (es) 2009-05-15 2012-06-06 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl
AU2010275367B2 (en) 2009-07-24 2015-09-03 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avB5 integrin
US8563694B2 (en) 2009-07-31 2013-10-22 Medarex, Inc. Fully human antibodies to BTLA
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
PL2529033T3 (pl) 2010-01-26 2017-10-31 Nat Jewish Health Sposoby do przewidywania ryzyka, diagnozowania i prognozowania zaburzeń płucnych
WO2011106723A2 (en) * 2010-02-26 2011-09-01 Lpath, Inc. Anti-paf antibodies
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
TWI629355B (zh) 2010-11-17 2018-07-11 中外製藥股份有限公司 具有替代血液凝固第ｖｉｉｉ因子之功能的多重專一性抗原結合分子
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
EP2762493B1 (de) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP2015505300A (ja) 2011-11-23 2015-02-19 アムジエン・インコーポレーテツド インターフェロンγに対する抗体を使用した治療方法
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
EP2877494B1 (de) 2012-07-23 2020-07-15 La Jolla Institute for Allergy and Immunology Ptprs und proteoglykane bei autoimmunkrankheiten
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
ES2823648T3 (es) 2013-04-01 2021-05-07 Univ California Métodos y composiciones para tratar y prevenir enfermedades asociadas con la integrina AVB8
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
EP3035964B1 (de) 2013-08-20 2020-09-23 Merck Sharp & Dohme Corp. Behandlung von krebs mit einer kombination aus einem pd-1 antagonisten und dinaciclib
AU2014312031A1 (en) 2013-08-29 2016-03-24 City Of Hope Cell penetrating conjugates and methods of use thereof
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
EP3084003A4 (de) 2013-12-17 2017-07-19 Merck Sharp & Dohme Corp. Ifn-gamma-gensignaturbiomarker der tumorreaktion auf pd-1 antagonisten
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
MX390904B (es) 2014-02-04 2025-03-21 Incyte Corp Combinación de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cáncer.
AU2015264528A1 (en) 2014-05-21 2016-11-03 Kyowa Hakko Kirin Co., Ltd. Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
US10414814B2 (en) 2014-07-03 2019-09-17 City Of Hope Tumor-selective CTLA-4 antagonists
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
EP3185866A1 (de) 2014-08-25 2017-07-05 Pfizer Inc. Kombination aus einem pd-1-antagonisten und einem alk-inhibitor zur behandlung von krebs
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
AR103428A1 (es) 2015-01-16 2017-05-10 Hope City Anticuerpos de penetración celular
EP3816179A3 (de) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc-region-variante, mit einer modifizierten fcrn-bindungsdomäne
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
KR20170122810A (ko) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
CA2981504C (en) 2015-03-30 2023-10-24 City Of Hope Mechanically interlocking complexes
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
EP3292147A1 (de) 2015-05-07 2018-03-14 NovImmune SA Verfahren und zusammensetzungen zur diagnose und behandlung von erkrankungen bei patienten mit erhöhten werten von cxcl9 und anderen biomarkern
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CN114990141A (zh) 2015-05-15 2022-09-02 希望之城 嵌合抗原受体组合物
CA2986126A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
TW201718023A (zh) 2015-08-06 2017-06-01 世代好公司 細胞滲透性蛋白質－抗體結合物及使用方法
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
AU2016315892B2 (en) 2015-09-02 2023-06-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
TW201733621A (zh) 2015-12-10 2017-10-01 世代好公司 細胞穿透性之花青耦合抗體
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
US10912776B2 (en) 2015-12-24 2021-02-09 Corvus Pharmaceuticals, Inc. Methods of treating cancer
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
CN108884169B (zh) 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
KR20180103150A (ko) 2016-01-25 2018-09-18 화이자 인코포레이티드 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합
RU2746754C2 (ru) 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
EP3445393A4 (de) 2016-04-20 2020-08-05 Merck Sharp & Dohme Corp. Cmv-neutralisierende antigenbindende proteine
PE20181889A1 (es) 2016-04-28 2018-12-11 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
CA3172367A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
MX2019003994A (es) 2016-10-14 2019-09-19 Merck Sharp & Dohme Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
MX2019004766A (es) * 2016-10-24 2019-09-27 Novimmune Sa Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma.
US20190263926A1 (en) 2016-10-28 2019-08-29 Astute Medical, Inc. Use of Antibodies to TIMP-2 for the Improvement of Renal Function
WO2018089967A1 (en) 2016-11-14 2018-05-17 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
IL315837A (en) 2017-04-13 2024-11-01 Sairopa B V Anti-SIRP-alpha antibodies
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US11680110B2 (en) 2017-07-31 2023-06-20 Hoffmann-La Roche Inc. Three-dimensional structure-based humanization method
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
EP3705496A4 (de) 2017-11-01 2021-12-08 Chugai Seiyaku Kabushiki Kaisha Antikörpervariante und isoform mit herabgesetzter biologischer aktivität
JOP20200131A1 (ar) 2017-11-17 2020-05-28 Merck Sharp & Dohme أجسام مضادة خاصة بنسخة تشبه جلوبيولين مناعي 3 (ilt3) واستخدامتها
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US12358984B2 (en) 2018-02-13 2025-07-15 Merck Sharp & Dohme Llc Methods for treating cancer with anti-PD-1 antibodies
CN112334485B (zh) 2018-04-06 2024-09-27 百进生物科技公司 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
AU2019249273A1 (en) 2018-04-06 2020-10-15 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
WO2020006568A1 (en) 2018-06-29 2020-01-02 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2020041758A1 (en) 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
EP3849606A4 (de) 2018-09-13 2022-06-29 Merck Sharp & Dohme Corp. Kombination aus einem pd-1-antagonisten und einem lag3-antagonisten zur behandlung von kolorektalem krebs mit nicht-mikrosatelliteninstabilität/kompetenter fehlanpassungsreparatur
CN113015746A (zh) 2018-09-19 2021-06-22 拉荷亚免疫研究所 在类风湿性关节炎中的ptprs和蛋白聚糖
EP3856343A1 (de) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9-mittel und zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CN120939219A (zh) 2019-05-13 2025-11-14 瑞泽恩制药公司 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
US20230053328A9 (en) 2019-05-24 2023-02-16 Pfizer Inc. Combination therapies using cdk inhibitors
EP3976090A1 (de) 2019-05-24 2022-04-06 Pfizer Inc. Kombinationstherapien mit cdk-hemmern
WO2020252029A1 (en) 2019-06-11 2020-12-17 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
TW202137984A (zh) 2019-10-29 2021-10-16 日商衛材R&D企管股份有限公司 用於治療癌症之PD-1拮抗劑、VEGFR/FGFR/RET酪胺酸激酶抑制劑及CBP/β-連環蛋白抑制劑之組合
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
EP4090681A1 (de) 2020-01-17 2022-11-23 Biolegend, Inc. Anti-tlr7-mittel und zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
EP4118105A2 (de) 2020-03-09 2023-01-18 Pfizer Inc. Cd80-fc-fusionsprotein und verwendungen davon
CA3173490A1 (en) * 2020-04-06 2021-10-14 Biliang HU Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling
CN115996951A (zh) 2020-04-30 2023-04-21 赛罗帕私人有限公司 抗cd103抗体
MX2022014180A (es) 2020-05-13 2022-12-02 Pfizer Metodos, terapias y usos para tratar cancer.
KR20230023802A (ko) 2020-06-25 2023-02-17 머크 샤프 앤드 돔 엘엘씨 세린 413에서 인산화된 타우를 표적화하는 고친화도 항체
WO2022003554A1 (en) 2020-07-01 2022-01-06 Pfizer Inc. Biomarkers for pd-1 axis binding antagonist therapy
US20230303654A1 (en) 2020-08-11 2023-09-28 City Of Hope Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
EP4208482A1 (de) 2020-09-02 2023-07-12 Pharmabcine Inc. Kombinationstherapie aus einem pd-1-antagonisten und einem antagonisten für vegfr-2 zur behandlung von patienten mit krebs
MX2023003034A (es) 2020-09-14 2023-04-10 Pfizer Metodos, terapias y usos para tratar el cancer.
CA3192509A1 (en) 2020-09-24 2022-03-31 Yogita Krishnamachari Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
CN117043194A (zh) 2021-01-29 2023-11-10 默沙东有限责任公司 程序性死亡受体1（pd-1）抗体的组合物以及获得所述组合物的方法
CN112794903B (zh) * 2021-04-14 2021-06-25 广州市雷德生物科技有限公司 一种特异性结合IFN-γ的抗体及其应用
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
JP2025511000A (ja) 2022-03-28 2025-04-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト インターフェロンガンマバリアントおよびこれを含む抗原結合分子
CN119301155A (zh) 2022-07-19 2025-01-10 百进生物科技公司 抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
IL323023A (en) 2023-03-13 2025-10-01 Regeneron Pharma Combination of PD-1 and LAG-3 inhibitors for improved efficacy in melanoma treatment
WO2024243217A1 (en) 2023-05-25 2024-11-28 BioLegend, Inc. Ceacam6 binding antibodies and antigen-binding fragments thereof
WO2025072313A1 (en) 2023-09-27 2025-04-03 BioLegend, Inc. Anti-gpc4 antibodies
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2025226695A1 (en) 2024-04-23 2025-10-30 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN118243913B (zh) * 2024-05-29 2024-08-23 上海秤信生物科技有限公司 一种质控品保存液及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon

Also Published As

Publication number Publication date
EP1135415A1 (de) 2001-09-26
US20020091240A1 (en) 2002-07-11
JP2002531466A (ja) 2002-09-24
CN1214043C (zh) 2005-08-10
AU764211B2 (en) 2003-08-14
MXPA01005515A (es) 2003-07-14
CA2352572C (en) 2010-04-20
US6329511B1 (en) 2001-12-11
CA2352572A1 (en) 2000-06-08
AU764211C (en) 2006-03-30
EP1135415A4 (de) 2004-09-22
US7183390B2 (en) 2007-02-27
AU2033100A (en) 2000-06-19
KR100483494B1 (ko) 2005-04-15
DE69942671D1 (de) 2010-09-23
HK1044159A1 (zh) 2002-10-11
CN1334821A (zh) 2002-02-06
EP1135415B1 (de) 2010-08-11
WO2000032634A1 (en) 2000-06-08
KR20010099807A (ko) 2001-11-09
WO2000032634A9 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
ATE477273T1 (de) Humanisierte antikoerper gegen gamma-interferon
MX9602971A (es) Anticuerpos humanizados contra la molecula vla-4 de adhesion de leucocitos.
DE69433406T2 (de) Antikörper gegen cd40
NO20053435L (no) Immunoglobulinvarianter og anvendelser derav
NZ568769A (en) Human monoclonal antibodies against CD20
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DE69128543D1 (de) Monoklonale antikörper der maus
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
MX9704897A (es) Secuencias del anticuerpo anti-idiotipo monoclonal recombinante 3h1 relacionadas con el antigeno carcinoembrionico humano.
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
TNSN06133A1 (en) Immunoglobulin variants and uses thereof
PT1200126E (pt) Utilização de anticorpos monoclonais específicos de cd28 para a preparação de uma composição farmacêutica para o tratamento de infecções virais
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
DE60334550D1 (de) Igg2 antikörper gegen exkretion sekretion antigenen von leishmania promastigoten oder amastigoten
ES2051870T3 (es) Anticuerpo monoclonal capaz de suprimir la proliferacion de linfocitos t.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties